Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m out in the field today can’t do it till tonight
Presentation is now up. If you can post it that would be great. Thanks
Yes my bad. I was just going over it again to make sure
Look at right corner. From January Park City Utah.
Old news ?
Great
Hmmm
Are we getting something
Monday ?
That’s old. Friday’s has not been uploaded yet. Maybe tomorrow.
Conclusion are not bad but far from conclusive of a blockbuster drug
Just too soon to determine anything
Thus price sit where it is
Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat from the 6th Global NASH Congress
https://hepionpharma.com/wp-content/uploads/2023/01/NASH_TAG_2023_Final.pdf
I’m sure you are. I’ve seen your past post history.
I'm comforted by knowing that
Don’t worry Makin bought more. Watch out!
Hope so
Want to see this explode Monday
Hate those buy the rumor and sell the news events
It's 4:pm now in England. Will we get results before or after today's market close ?
I say this afternoon
Todays PR answered
My question
They are in phase 2 for 2 Indications
Plenty of time before this stock heats up
Unless
You know know something insider ???
What’s your take on tomorrow’s updates?
CEO speaks in the UK tomorrow. Expect another PR!
Cool
Have they started trials ?
The FDA usually likes to see results from trials
$HEPA: Incredible news today........ now $0.80
$HEPA EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
This patent applies to 38 COUNTRIES !!!!!!!!!
You see where $MDGL is over $300.............. we are a DIRECT COMPETITOR to them.
Thats where $HEPA should be.
GO $HEPA
News this AM. New European patent issued.
We could use a PDSB type of run here. All we need is that boom from Management.
No more dumping. This stock is actually trading now
Friday will be here soon enough. Nash conference in the UK. PR incoming
Nice move up today
Guess your waiting for this turd to head back down before you pump again.
Your guess is as good as mine. He seems to say HEPA will have its day! Crap shoot.
Do you think that guy will come back here and pump this now that it's down ?
And pumps them too
Real
??
Mr know it all. Jumps on momo plays than disappears.
Somebody told me Makin Ez money in iHub jail
Lol
What a tool
Haven't seen peer reviewed paper
What is it that this company claims to do and where are they In terms of trials or working with the FDA
Can some one post a link please
Without the biggest cheerleader we seem to be stuck in the mud here. Rah rah rah.
Now I believe they are a legit company
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
https://finance.yahoo.com/news/hepion-pharmaceuticals-ring-nasdaq-stock-211500723.html
Come on company give us a damn update on some of the current trials. We know your sitting on this info. Your buddy Makin is saying the Nash space is where it’s at. Prove him right!
Believe they had around 44 mil in cash at the end of last Q. Just look at the last release.
Do you know their cash situation? Any change that they will do offering soon?
Updated slide deck on their website btw.
Stick to landscaping and harass another board.
are you referring to the Brookline analysts report out ? I'll assume yes
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31.
Analyst James Molloy writes that his recommendation is based primarily on expectations for Hepion’s rencofilstat, a cyclophilin inhibitor that is being developed to treat non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) associated with NASH.
Please post link otherwise it's fake
Upwards and onwards my friend.. New buy rating out today with a 4 PT.
Nope. You are correct
Followers
|
82
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2150
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |